

## **Title:** Navigating the Neurological Aftermath of COVID-19: An In-Depth Exploration

*Maliha Butt, MD, Shavy Nagpal\*, MD, Ellex Phillips, MD, MBA, Shazia Q. Shah, MD, Zeryab Dogar, MBBS, Hanyou Loh, MS-4, Sakshi Mishra, MD, Rupalakshmi Vijayan\*\*, MD, Rishan Jeyakumar, MS-4, Sarabjot Singh Makkar, MD, Samia Jahan, MD, Gabriela Marie Díaz, MS-3, Hudson Franca, MD, Schaza Javed, MD, Marie-Pierre Belizaire, MD, MPH, Manoj Reddy Somagutta, MD*

*\*Division of Clinical & Translational Research, Larkin Health System, South Miami, FL, USA*

*\*\*St Elizabeth Health Centre-Boardman, Ohio*

[Shav.nagpal@gmail.com](mailto:Shav.nagpal@gmail.com)

### **ABSTRACT**

**Background:** The COVID-19 pandemic caused by SARS-CoV-2 has affected millions of people and can result in both immediate and prolonged neurological effects, including severe complications. While numerous studies have explored the occurrence and consequences of neurological issues in COVID-19, they have often involved limited sample sizes.

**Purpose:** This paper aims to determine the overall occurrence of neurological complications in COVID-19, examine their links with patient demographics, and assess their impact on patient outcomes. Additionally, it seeks to provide an overview of the current understanding of the underlying mechanisms.

**Methodology:** Two systematic reviews were conducted to investigate acute and chronic neurological complications associated with COVID-19. A comprehensive search of medical databases was performed, and relevant studies were evaluated following PRISMA guidelines. Meta-analysis was carried out using the Mantel-Haenszel method, with subgroup analysis and meta-regression used to assess heterogeneity.

**Results:** The analysis of acute complications included 20,011 patients with an average age of 58.1 years and a slight male predominance (55.2%). Common neurological symptoms included loss of taste and smell, headaches, acute encephalopathy, and stroke. For the analysis of long-term complications, 2,094 patients were included. Survivors of COVID-19 experienced ongoing neurological issues ranging from sensory impairments to fatigue, headaches, strokes, and even cognitive and psychiatric problems.

**Conclusion:** By examining various neurological symptoms, this study found a significant association between these manifestations and worse overall outcomes, especially in patients over 60 years old. Identifying high-risk individuals and maintaining a high level of suspicion are crucial for enhancing our understanding of the underlying mechanisms, validating biomarkers, and improving the management of these neurological issues.

**Keywords:** COVID-19, SARS-Cov-2, Neurological Sequelae, Neurological Manifestations, Acute Neurological Complications, Chronic Neurological Complications

## **INTRODUCTION**

COVID-19 has raised numerous questions about its impact on pre-existing health conditions, multi-organ complications, and long-term effects on various bodily systems. Notably, the nervous system has emerged as a particularly concerning area of concern. The spectrum of neurological effects associated with COVID-19 spans from mild issues like changes in taste and smell to severe conditions such as acute encephalopathy, cerebral hemorrhage, and acute myelitis. Patients who experience severe neurological complications appear to face increased risks in terms of both mortality and the severity of their illness. Furthermore, a noteworthy proportion of COVID-19 survivors seem to develop neuropsychiatric disorders, neurodegenerative conditions, and neuropathies in the weeks to months following their acute illness. The involvement of the nervous system during a SARS-Cov-2 infection has thus been linked to substantial morbidity and mortality.

Although several observational studies conducted in clinical settings have examined the neurological effects of COVID-19 and their impact on patient outcomes, many of these studies have been limited by their small sample sizes, making it challenging to generalize their findings to the broader population. In this systematic review and meta-analysis, we aim to aggregate observational studies with similar objectives and structures to establish the incidence of neurological complications associated with COVID-19. Additionally, we seek to explore the associations between these complications and clinical characteristics while also assessing their influence on patient outcomes. This review provides an overview of common neurological manifestations of COVID-19 and endeavors to synthesize our current understanding of the pathophysiology and epidemiology of neurological complications in the context of this viral infection.

## **METHODS**

We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Our study protocol was registered on PROSPERO with the ID CRD42020209734 on September 22, 2020. To gather relevant literature, we conducted an extensive search on databases including PubMed, Scopus, Google Scholar, and ScienceDirect.

For the analysis of acute neurological complications associated with COVID-19, our search strategy involved various combinations of keywords such as "COVID-19," "neurology," "nervous system," "neurological manifestation," "acute complications," and "neurological sequelae." Additionally, we reviewed the reference lists of existing review articles and conducted manual searches to identify any additional pertinent studies.

Our inclusion criteria encompassed the following: (1) Original studies, such as cohort studies, case-control studies, and cross-sectional studies, (2) confirmation of COVID-19 through laboratory diagnosis in the study population, (3) studies reporting data on neurological manifestations, symptoms, or complications in COVID-19 patients, (4) inclusion of adult patients (age >18 years), and (5) articles published in the English language. We excluded studies falling into the following categories: case reports, case series, non-original articles like review articles (including meta-analyses), letters, or comments.

For our analysis of long-term neurological complications of COVID-19, we manually searched the medical literature using various search terms, such as "chronic neurological complications,"

"long-term complications," "COVID-19," and "COVID-19 long haulers." We selected articles based on the following criteria: (1) Observational studies, including cohort studies, case-control studies, and cross-sectional studies, (2) inclusion of patients with laboratory-confirmed COVID-19, (3) study participants limited to adults (age >17 years), and (4) a follow-up period of at least one month after the initial infection. We excluded articles not written in English, as well as case reports, case series, non-original articles like review articles (including meta-analyses), letters, or comments.

**Risk Assessment:** We evaluated study quality using the National Institutes of Health (NIH) and National Heart, Lung, and Blood Institute's (NHLBI) Quality Assessment Tool, along with the Cochrane Risk of Bias assessment tool. Two independent investigators assessed each study's quality, looking for flaws in design or implementation. Key aspects assessed included clear objectives, well-defined study populations, adequate participation rates, similar patient recruitment, sample size justification, appropriate exposure measurement, sufficient time frames, clear outcome definitions, blinding, minimal loss to follow-up, and adjustment for confounders. Ratings were recorded for each aspect, and an overall study rating was assigned. In cases of disagreement, reviewers discussed the article to reach a consensus, with a third author reconciling differences if necessary.

**Risk of Bias Assessment:** We jointly assessed bias using Cochrane's Risk of Bias tool for Single Studies, considering multiple potential bias domains, such as random sequence generation, allocation concealment, blinding of participants and outcomes, incomplete outcome data, and selective reporting. A low or high-risk rating was assigned to each domain, allowing an overall risk level to be determined based on these judgements. Studies with high bias risks were considered for exclusion.

**Data Extraction:** Data extraction was conducted using the Google Sheets app. Initially, a pilot extraction sheet was created and later modified for final review. Two separate groups of co-authors independently reviewed included articles for necessary information. Missing data was requested from corresponding authors, and any disagreements between reviewers were resolved through discussion and consensus.

**Data Synthesis:** Meta-analysis was performed using Cochrane Review Manager (version 5.4) and the Mantzel-Haenszel statistical method. A random-effects model was applied to account for inter-study variability. Only studies reporting outcomes in both patients with and without neurological manifestations were included. Composite poor outcomes, including severe/critical COVID-19 infection, ICU admission, mechanical ventilation, and mortality, were analyzed. Risk ratios with 95% confidence intervals were reported for outcomes in patients with neurological manifestations compared to those without. Subgroup analysis based on age (average age below or above 60 years) was conducted to explore sources of heterogeneity. Results were displayed in a forest plot with effect sizes, and a funnel plot was considered if the minimum number of studies for a meta-analysis was reached. Additionally, univariate meta-regression was performed to identify confounding factors affecting study outcomes.

## RESULTS

We identified 350 articles from medical literature databases, journals, and reference lists. After removing duplicates, 296 original articles remained. Through sequential screening of abstracts

and full-text articles, we selected 32 eligible studies. Eight of these studies had a high risk of bias and were excluded from the final analysis. Ultimately, 26 studies, primarily cohort studies (16), along with some observational studies and one case series, were included in the systematic review. All these studies collected patient data between January and November 2020.

For the analysis of long-term neurological effects of COVID-19, we conducted a thorough manual search based on the mentioned criteria. After reviewing available studies, we incorporated six cohort studies into our analysis. The limited amount of data currently accessible in this area is reflected in the small number of articles included.

**Table 1: Demographics [1-6]**

<b>Demographics</b>	<b>Acute Neurological Complications</b>	<b>Long-Term Neurological Complications</b>
<b>Total Patients Analyzed</b>	20,011	2,094
<b>Average Age</b>	58.1 years	55.7 years
<b>Gender Distribution</b>	Male: 55.2%	Male: 51.0%
<b>Geographic Distribution (%)</b>	North America: 57.3%	-
	Europe: 30.2%	-
	Asia: 10.3%	-
	Africa: 0.5%	-
<b>Hospitalized Patients (%)</b>	97%	-
<b>Severity of COVID-19 (%)</b>	Severe to Critical: 28.5%	Severe: 62.1%
		Mild/Moderate: 30.2%
		Critical: 6.7%
<b>Common Comorbidities (%)</b>	Hypertension: 39.7%	Hypertension: 26.4%
	Diabetes: 28.8%	Diabetes: 11.7%
	Heart Disease: 28.0%	Heart Disease: 7.9%
	-	COPD: 3.6%
	-	Malignancy: 2.4%
	-	Neurological Disorders: 2.2%
	-	CKD: 2.0%
<b>Common Presenting Symptoms (%)</b>	Fever: 56%	Insomnia: 22.2%
	Cough: 55%	Mood & Anxiety Disorders: 17.5%
	SOB: 46.2%	Anosmia: 14.7%
	Fatigue: 43.6%	Headache: 9.36%

Demographics	Acute Neurological Complications	Long-Term Neurological Complications
	Gastrointestinal Symptoms: 39%	Ageusia: 7.31%
		Dizziness: 5.97%
		Numbness/Tingling, Tinnitus/Blurred
		Vision (Both at 1.43%)
Quality of Life Assessment	EQ-5D-5L, SF-36, PHQ-9, GAD-7, SRGQ	EQ-5D-5L, SF-36, PHQ-9, GAD-7, SRGQ
Cognitive Function Assessment	NIH Toolbox	NIH Toolbox
	Attention: Median T-score 41.5	-
	Working Memory: Median T-score 43	-

### Quality Assessment

#### Acute Neurological Complications:

- 24 out of 32 studies were of good quality and low risk of bias.
- One study with low risk of bias was excluded due to a small eligible population.
- 7 studies had a high risk of bias and were excluded.

#### Long-Term Neurological Complications:

- 6 out of 7 long-term studies were of good quality and lower risk of bias.
- One study of poor quality with potential biases in data presentation was excluded.

**Table 2: Acute Neurological Complications**

Complication/Manifestation	Incidence Rate (%)	Mean Delay (Days)
Ageusia	27.4%	11.3 (Range: 2 - 28)
Anosmia	21.00%	
Headache	17.66%	
Delirium/Acute Encephalopathy	10.99%	
Stroke	3.75%	
Peripheral Nervous System (PNS) Disease	3.16%	
Coma	1.69%	
Seizures	1.44%	

**Table 3: Association Between Neurological Complications and Poor Composite Outcome**

Analysis	Risk Ratio (95% CI)	Heterogeneity (I <sup>2</sup> )	Subgroup Analysis
Neurological Complications vs. No Neurological Complications	2.06 (1.57 - 2.70)	94%	Based on Average Age: Older and Younger than 60 Years
			- Older than 60 Years: Z value: 6.45, P < 0.00001
			- Younger than 60 Years: Z value: 1.21, P < 0.23
			- Age Subgroup Analysis Did Not Explain Heterogeneity

**Table 4: Mortality in COVID-19 Patients with Neurological Manifestations**

	Risk Ratio (RR)	95% CI	P-Value
Overall	1.14	0.80 - 1.63	0.47
Subgroup Analysis			
Age > 60 Years	1.75	1.14 - 2.70	0.01
Univariate Analysis			
Age	N/A	N/A	0.754
Hypertension	N/A	N/A	0.449
Diabetes Mellitus	N/A	N/A	0.228
Hyperlipidemia	N/A	N/A	0.185
Pre-existing Neuro	N/A	N/A	0.501
Cancer	N/A	N/A	0.294
COPD	N/A	N/A	0.686
CKD	N/A	N/A	0.391
Heart Disease	N/A	N/A	0.463
Heterogeneity (I <sup>2</sup> )	90%		

## DISCUSSION

Neurological complications in COVID-19 are diverse, ranging from mild symptoms like headache and anosmia to severe conditions including encephalitis and stroke. These complications can persist long after the acute infection. The overall incidence is around 25.2%. Severe neurological issues are less common than cardiovascular problems but can have significant morbidity and mortality.

Gustatory dysfunction (GD) and anosmia are common symptoms, often occurring together. These symptoms can vary in prevalence across regions and may be underreported in severe cases.

Delirium and acute encephalopathy are significant concerns, especially in older patients, and can be early signs of COVID-19. They are associated with adverse outcomes and increased mortality. Management includes identifying high-risk patients and addressing underlying causes, with steroids showing promise in treatment. [7-56]

Stroke in COVID-19 is a rare but serious complication, often occurring after the first week of infection. It's associated with endothelial damage and inflammation due to the virus, leading to large artery strokes. The incidence is around 3.86%, with a higher risk in older, male, and comorbid individuals.

Seizures can occur in COVID-19, especially in serious cases, and may be due to various causes, including fever, hypoxia, and underlying conditions. The incidence is approximately 1.44%.

Coma in COVID-19 is associated with poor outcomes, especially in patients over 60. It can result from various factors, including sedation in the ICU and underlying encephalopathy. The incidence is around 1.69%. [57-88]

Headache is a common neurological symptom in COVID-19, possibly caused by direct virus interaction with the nervous system or inflammation-related factors. It's among the top symptoms after fever, cough, myalgia, and dyspnea.

The incidence of headache in COVID-19 varies, with rates from 5% to 37% in different studies. Anosmia and ageusia are often associated with headaches.

COVID-19-related headaches can have various characteristics, including migraine-like features and unusual aspects like intractable headaches. Some patients experience persistent or late-onset headaches after the acute phase of the illness.

Treatment typically starts with acetaminophen and may progress to NSAIDs if necessary.

Refractory headaches may require more specialized evaluation. In some cases, headaches can persist for several months as a long-term symptom of COVID-19. [89-105].

COVID-19 is associated with various peripheral nervous system (PNS) complications, including neuralgias, Guillain-Barre Syndrome (GBS), cranial nerve disorders, neuro-ophthalmological issues, sensorineural hearing loss, and autonomic dysfunction.

The incidence of PNS disorders in COVID-19 varies widely, with reports ranging from 9% to 60%. In our analysis, PNS disorders occurred in 3.56% of COVID-19 patients, with peripheral neuropathies and cranial nerve disorders being the most common.

PNS complications may result from direct viral invasion or systemic inflammation. COVID-19-related GBS is more common in older patients and those with severe disease. It can precede other COVID-19 symptoms and often has a poor prognosis.

Dysautonomia, characterized by blood pressure instability, orthostatic hypotension, and bladder/bowel dysfunction, is common in critically ill COVID-19 patients and may be related to nerve pathway disruption.

New-onset neuromuscular diseases like Myasthenia Gravis have been reported in COVID-19 patients, possibly due to molecular mimicry.

Treatment for PNS complications varies based on the diagnosis but often includes steroids, plasma exchange, and immunoglobulins for GBS and related disorders. Opioids and anticonvulsants should be avoided for neuralgic pain in COVID-19 patients. [106-119]

### **Fatigue**

Fatigue and myalgia are common post-SARS-CoV-2 infection symptoms, with varying prevalence rates in studies. Factors such as gender, disease severity, age, BMI, and pre-existing depression may influence the likelihood of experiencing long-term fatigue.

The mechanisms behind acute and chronic fatigue involve immune and nervous system components, including neuroinflammation and endothelial cell damage. There is no definitive causal mechanism for chronic fatigue, and further research is needed to better understand its etiology, clinical course, and treatment. [120-154].

### **LIMITATIONS OF THE STUDY**

This systematic review analyzes the impact of individual neurological complications on COVID-19 mortality. Caution is needed due to the limited number of studies, potential bias, and lack of control groups. Only stroke and acute encephalopathy were included in the meta-analysis. Severe COVID-19 may contribute to severe neurological disorders, but causal relationships need further investigation. Future studies should address confounding factors and clarify COVID-19's relationship with neurological complications.

### **CONCLUSION**

Acute neurological disorders in COVID-19 are common, associated with poor outcomes and higher mortality, especially in those over 60 years. Survivors can experience chronic complications, including sensory issues, fatigue, stroke, cognitive, and psychiatric problems. Ongoing research, like the BRAINSTORM study, is crucial for better understanding and targeted management of these conditions. Healthcare workers should maintain a high index of suspicion for early detection.



## REFERENCES

1. Faber I, Brandão PRP, Menegatti F, de Carvalho Bispo DD, Maluf FB, Cardoso F. Coronavirus Disease 2019 and Parkinsonism: A Non-post-encephalitic Case. *Mov Disord*. 2020;35(10):1721-1722.
2. Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, et al. A case of probable Parkinson's disease after SARS-CoV-2 infection. *Lancet Neurol*. 2020;19(10):804-805.
3. Ng WH, Tipih T, Makoah NA, Vermeulen J, Goedhals D, Sempa J, et al. Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis. *mBio*. 2021;12(1):e03647-20.
4. Honardoost M, Janani L, Aghili R, Emami Z, Khamseh ME. The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis. *Cerebrovasc Dis*. 2021;50(2):132-140.
5. Underlying Medical Conditions for Clinicians. Centers for Disease Control and Prevention. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html>.
6. Feehan J, Apostolopoulos V. Is COVID-19 the worst pandemic? [published online ahead of print, 2021 Feb 6]. *Maturitas*. 2021;S0378-5122(21)00018-9.
7. Worldometers.info. Dover, Delaware, U.S.A. Accessed on 26 April, 2021
8. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ*. 2020;370:m3026.
9. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med*. 2003;348(20):1953-1966.
10. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res*. 2020;24:91-98.
11. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. *ACS Chem Neurosci*. 2020;11(7):995-998.
12. Steardo L, Steardo L Jr, Zorec R, Verkhatsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. *Acta Physiol (Oxf)*. 2020;229(3):e13473.
13. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun*. 2020;87:18-22.
14. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. *Clin Neurol Neurosurg*. 2020;194:105921.

15. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nat Med*. 2020;26(5):681-687.
16. Vojdani A, Vojdani E, Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. *Front Immunol*. 2021;11:617089.
17. Franke C, Ferse C, Kreye J, Reincke SM, Sanchez-Sendin E, Rocco A, et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. *Brain Behav Immun*. 2021;93:415-419.
18. Ho BE, Ho AP, Ho MA, Ho EC. Case report of familial COVID-19 cluster associated with High prevalence of anosmia, ageusia, and gastrointestinal symptoms. *IDCases*. 2020;22:e00975.
19. Homma Y, Watanabe M, Inoue K, Moritaka T. Coronavirus Disease-19 Pneumonia with Facial Nerve Palsy and Olfactory Disturbance. *Intern Med*. 2020;59(14):1773-1775.
20. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. *Lancet Neurol*. 2020 Sep;19(9):767-783.
21. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. *Radiology*. 2020;296(2):E119-E120.
22. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol*. 2020;77(6):683-690.
23. Khedr EM, Abo-Elfetoh N, Deaf E, Hassan HM, Amin MT, Soliman RK, et al. Surveillance Study of Acute Neurological Manifestations among 439 Egyptian Patients with COVID-19 in Assiut and Aswan University Hospitals. *Neuroepidemiology*. 2021;55(2):109-118.
24. Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak T, Tenorio EL, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study [published correction appears in *Lancet Psychiatry*. 2020 Jul 14;:]. *Lancet Psychiatry*. 2020;7(10):875-882.
25. Parsons T, Banks S, Bae C, Gelber J, Alahmadi H, Tichauer M. COVID-19-associated acute disseminated encephalomyelitis (ADEM). *J Neurol*. 2020;267(10):2799-2802.
26. Valiuddin H, Skwirsk B, Paz-Arabo P. Acute transverse myelitis associated with SARS-CoV-2: A Case-Report. *Brain Behav Immun Health*. 2020;5:100091.
27. Jain R, Young M, Dogra S, Kennedy H, Nguyen V, Jones S, Bilaloglu S, et al. COVID-19 related neuroimaging findings: A signal of thromboembolic complications and a strong prognostic marker of poor patient outcome. *J Neurol Sci*. 2020 Jul 15;414:116923.

28. Lechien JR, Chiesa-Estomba CM, Place S, Laethem YV, Cabaraux P, Mat Q, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. *J Intern Med*. 2020;288(3):335-344.
29. Prasitlumkum N, Chokesuwattanaskul R, Thongprayoon C, Bathini T, Vallabhajosyula S, Cheungpasitporn W. Incidence of Myocardial Injury in COVID-19-Infected Patients: A Systematic Review and Meta-Analysis. *Diseases*. 2020;8(4):40.
30. Linschoten M, Peters S, van Smeden M, Jewbali LS, Schaap J, Siebelink HM, et al. CAPACITY-COVID collaborative consortium. Cardiac complications in patients hospitalised with COVID-19. *Eur Heart J Acute Cardiovasc Care*. 2020 Dec;9(8):817-823.
31. Vaira LA, Lechien JR, Salzano G, Salzano FA, Maglitto F, Saussez S, et al. Gustatory Dysfunction: A Highly Specific and Smell-Independent Symptom of COVID-19 [published online ahead of print, 2020 Sep 30]. *Indian J Otolaryngol Head Neck Surg*. 2020;1-3.
32. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection [published online ahead of print, 2020 Sep 11]. *Neuroscientist*. 2020;1073858420956905.
33. Liou JM, Chen MJ, Hong TC, Wu MS. Alteration of taste or smell as a predictor of COVID-19. *Gut*. 2021;70(4):806-807.
34. Hajikhani B, Calcagno T, Nasiri MJ, Jamshidi P, Dadashi M, Goudarzi M, et al. Olfactory and gustatory dysfunction in COVID-19 patients: A meta-analysis study. *Physiol Rep*. 2020 Sep;8(18):e14578.
35. Cirillo N, Bizzoca ME, Lo Muzio E, Cazzolla AP, Lo Muzio L. Gustatory dysfunction in COVID-19 patients: a rapid systematic review on 27,687 cases. *Acta Odontol Scand*. 2021 Jan 15:1-8.
36. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Snchez-Larsen A, Layos-Romero A, Garcia-Garcia J., et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. *Neurology*. 2020;95(8):e1060-e1070.
37. Huart C, Philpott C, Konstantinidis I, Altundag A, Whitcroft KL, Trecca EMC, et al. Comparison of COVID-19 and common cold chemosensory dysfunction. *Rhinology*. 2020 Dec 1;58(6):623-625.
38. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. *Brain Behav Immun*. 2020;88:11-16.
39. Klopfenstein T, Kadiane-Oussou NJ, Toko L, Royer P-Y, Lepiller Q, Gendrin V, et al. Features of anosmia in COVID-19. *Med Mal Infect*. 2020;50(5):436-439. doi:10.1016/j.medmal.2020.04.006
40. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the

- coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol.* 2020;277(8):2251-2261.
41. Poncet-Megemont L, Paris P, Tronchere A, Salazard JP, Pereira B, Dallel R, et al. High Prevalence of Headaches During Covid-19 Infection: A Retrospective Cohort Study. *Headache.* 2020;60(10):2578-2582.
  42. Alkeridy WA, Almaghlouth I, Alrashed R, Alayed K, Binkhamis K, Alsharidi A, et al. A Unique Presentation of Delirium in a Patient with Otherwise Asymptomatic COVID-19. *J Am Geriatr Soc.* 2020;68(7):1382-1384.
  43. Beach SR, Praschan NC, Hogan C, Dotson S, Merideth F, Kontos N, et al. Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement. *Gen Hosp Psychiatry.* 2020;65:47-53.
  44. Butt I, Sawlani V, Geberhiwot T. Prolonged confusional state as first manifestation of COVID-19. *Ann Clin Transl Neurol.* 2020 Aug;7(8):1450-1452.
  45. Tay HS, Harwood R. Atypical presentation of COVID-19 in a frail older person. *Age Ageing.* 2020 Jul 1;49(4):523-524.
  46. Kennedy M, Helfand BKI, Gou RY, Gartaganis SL, Webb M, Moccia JM, et al. Delirium in Older Patients With COVID-19 Presenting to the Emergency Department. *JAMA Netw Open.* 2020;3(11):e2029540.
  47. Pun BT, Badenes R, Heras La Calle G, Orun OM, Chen W, Raman R, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study [published correction appears in *Lancet Respir Med.* 2021 Jan 27;:]. *Lancet Respir Med.* 2021;9(3):239-250.
  48. Hawkins M, Sockalingam S, Bonato S, Rajartnam T, Ravindran M, Gosse P, et al. A rapid review of the pathoetiology, presentation, and management of delirium in adults with COVID-19. *J Psychosom Res.* 2021;141:110350.
  49. Frontera JA, Sabadia S, Lalchan R, Fang T, Flusty B, Millar-Verneti P, et al. A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City. *Neurology.* 2021;96(4):e575-e586.
  50. Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS, et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. *Ann Clin Transl Neurol.* 2020;7(11):2221-2230.
  51. Cipriani G, Danti S, Nuti A, Carlesi C, Lucetti C, Di Fiorino M. A complication of coronavirus disease 2019: delirium. *Acta Neurol Belg.* 2020;120(4):927-932.
  52. Pandharipande P, Cotton BA, Shintani A, Thompson J, Pun BT, Morris JA, et al. Prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients. *J Trauma.* 2008;65(1):34-41.

53. Pandharipande P, Shintani A, Peterson J, Pun BT, Wilkinson GR, Dittus RS, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. *Anesthesiology*. 2006;104(1):21-26.
54. Helms J, Kremer S, Merdji H, Schenck M, Severac F, Clere-Jehl R, et al. Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients. *Crit Care*. 2020;24(1):491.
55. DeKosky ST, Kochanek PM, Valadka AB, Clark RSB, Chou SHY, Au AK, et al. Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients. *J Neurotrauma*. 2021;38(1):1-43.
56. Silva S. Neurotropism and Neuroinflammation in COVID-19 Patients With Delirium (BRAINSTORM).: Covid19 Clinical Trial. *Trial Bulletin.com*. <https://trialbulletin.com/lib/entry/ct-04785157>.
57. Pugin D, Vargas MI, Thieffry C, Schibler M, Groscurin O, Pugin J, et al. COVID-19-related encephalopathy responsive to high-dose glucocorticoids. *Neurology*. 2020;95(12):543-546.
58. Cao A, Rohaut B, Le Guennec L, Saheb S, Marois C, Altmayer V, et al. Severe COVID-19-related encephalitis can respond to immunotherapy. *Brain*. 2020;143(12):e102.
59. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. *N Engl J Med*. 2004;351(25):2611-2618.
60. Miller EC, Elkind MS. Infection and Stroke: an Update on Recent Progress. *Curr Neurol Neurosci Rep*. 2016 Jan;16(1):2.
61. Karimi L, Sales C, Crewther SG, Wijeratne T. Acute Ischemic Stroke in SARS-CoV, MERS-CoV, SARS-CoV-2: Neurorehabilitation Implications of Inflammation Induced Immunological Responses Affecting Vascular Systems. *Front Neurol*. 2020;11:565665.
62. Umapathi T, Kor AC, Venketasubramanian N, Tchoyoson Lim CC, Chuan Pang B, Yeo TT, et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). *J Neurol*. 2004;251(10):1227-1231.
63. Valencia-Enciso N, Ortiz-Pereira M, Zafra-Sierra MP, Espinel-Gómez L, Bayona H. Time of Stroke Onset in Coronavirus Disease 2019 Patients Around the Globe: A Systematic Review and Analysis. *J Stroke Cerebrovasc Dis*. 2020;29(12):105325.
64. Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. *JAMA*. 2020;324(22):2251-2252.
65. Merkle AE, Parikh NS, Mir S, Gupta A, Kamel H, Lin E, et al. Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza [published online ahead of print, 2020 Jul 2]. *JAMA Neurol*. 2020;77(11):1-7.
66. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. *Stroke* 2003;34:2518-2532.

67. Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? *Viruses* 2019;12:14.
68. Fifi JT, Mocco J. COVID-19 related stroke in young individuals. *Lancet Neurol.* 2020;19(9):713-715.
69. Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? *Clin Exp Rheumatol* 2020;38:337-342.
70. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. *N Engl J Med* 2020;382:e38.
71. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020;18:844-847.
72. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med.* 2021;384(8):693-704.
73. Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, et al. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. *JAMA Netw Open.* 2021;4(3):e213594.
74. Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno PR, Pujadas E, et al. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. *J Am Coll Cardiol.* 2020;76(16):1815-1826.
75. Strein M, Holton-Burke JP, Smith LR, Brophy GM. Prevention, Treatment, and Monitoring of Seizures in the Intensive Care Unit. *J Clin Med.* 2019;8(8):1177.
76. Khedr EM, Shoyb A, Mohammaden M, Saber M. Acute symptomatic seizures and COVID-19: Hospital-based study [published online ahead of print, 2021 May 5]. *Epilepsy Res.* 2021;174:106650.
77. Gaughan M, Connolly S, Direkze S, Kinsella JA. Acute new-onset symptomatic seizures in the context of mild COVID-19 infection [published online ahead of print, 2020 Sep 10]. *J Neurol.* 2020;1-3.
78. Riggs J.E. Neurologic manifestations of electrolyte disturbances. *Neurologic clinics.* 2002;20(1):227–239
79. Nikbakht F, Mohammadkhanizadeh A, Mohammadi E. How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms. *Mult Scler Relat Disord.* 2020;46:102535.
80. Rana A, Musto AE. The role of inflammation in the development of epilepsy. *J Neuroinflammation.* 2018;15(1):144.

81. Van Vliet EA, da Costa Araújo S, Redeker S, van Schaik R, Aronica E, Gorter JA. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. *Brain*. 2007;130(Pt 2):521-534
82. Nardone R, Brigo F, Trinka E. Acute Symptomatic Seizures Caused by Electrolyte Disturbances. *J Clin Neurol*. 2016;12(1):21-33.
83. Young GB. Coma. *Ann N Y Acad Sci*. 2009;1157:32-47.
84. Chou SH, Beghi E, Helbok R, Moro E, Sampson J, Altamirano V, et al. Global incidence of neurological manifestations among patients hospitalized with COVID-19 – A report for the GCS-NeuroCOVID consortium and the ENERGY consortium. *Jama Netw Open*. 2021 May 3;4(5):e2112131.
85. Abdo WF, Broerse CI, Grady BP, Wertenbroek AAACM, Vijlbrief O, Buise MP, et al. Prolonged Unconsciousness Following Severe COVID-19. *Neurology*. 2021;96(10):e1437-e1442.
86. Guilmot A, Maldonado Sloopjes S, Sellimi A, Bronchain M, Nahseeuw B, Belkhir L, et al. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. *J Neurol*. 2021;268(3):751-757.
87. Koutroumanidis M, Gratwicke J, Sharma S, Whelan A, Tan SV, Glover G. Alpha coma EEG pattern in patients with severe COVID-19 related encephalopathy. *Clin Neurophysiol*. 2021;132(1):218-225.
88. Waldman GJ, Thakur KT, Der Nigoghossian C, Spektor V, Mendiratta A, Bell M, et al. Multidisciplinary Guidance to Manage Comatose Patients with Severe COVID-19. *Ann Neurol*. 2020;88(4):653-655
89. Bobker SM, Robbins MS. COVID-19 and headache: A primer for trainees. *Headache*. 2020;60(8):1806-1811.
90. Bolay H, Gül A, Baykan B. COVID-19 is a real headache! *Headache*. 2020;60(7):1415-1421.
91. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) [published online ahead of print, 2021 Jan 23]. *J Neurol*. 2021;1-13.
92. Borges do Nascimento IJ, Cacic N, Abdulazeem HM, Caspar von Groote T, Jayarajah U, Weerasekera I, et al. Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis. *J Clin Med*. 2020;9(4):941.
93. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents*. 2020;55(3):105924.
94. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. *J Infect*. 2020;80(4):401-406

95. Agarwal S, Jain R, Dogra S, Krieger P, Lewis A, Nguyen V, et al. Cerebral Microbleeds and Leukoencephalopathy in Critically Ill Patients With COVID-19. *Stroke*. 2020;51(9):2649-2655.
96. Shafait, S., Alamgir, W., Yousaf, M., Manzal, M., Khattak, A., & Yousaf, M.. "Neurological manifestations of COVID-19 in patients admitted at a tertiary care hospital in Punjab, Pakistan". *PAFMJ*, 70(2), S439-43.
97. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol*. 2020;10(8):944-950.
98. Rocha-Filho PAS, Magalhães JE. Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia. *Cephalalgia*. 2020;40(13):1443-1451.
99. Magdy R, Hussein M, Ragaie C, Abdel-Hamid HM, Khallaf A, Rizk HI, et al. Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: A cross sectional study. *Cephalalgia*. 2020;40(13):1422-1431.
100. Belvis R. Headaches During COVID-19: My Clinical Case and Review of the Literature. *Headache*. 2020;60(7):1422-1426
101. Uygun Ö, Ertas M, Ekizoğlu E, Bolay H, Ozge A, Orhan EK, et al. Headache characteristics in COVID-19 pandemic-a survey study. *J Headache Pain*. 2020;21(1):121.
102. Arca KN, Starling AJ. Treatment-Refractory Headache in the Setting of COVID-19 Pneumonia: Migraine or Meningoencephalitis? Case Report [published online ahead of print, 2020 Jun 25]. *SN Compr Clin Med*. 2020;1-4
103. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens J, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021;27(4):601-615.
104. MaassenVanDenBrink A, de Vries T, Danser AHJ. Headache medication and the COVID-19 pandemic. *J Headache Pain*. 2020;21(1):38.
105. Graham EL, Clark JR, Orban ZS, Lim PH, Szymansk AL, Taylor C, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". *Ann Clin Transl Neurol*. 2021;8(5):1073-1085.
106. Andalib S, Biller J, Di Napoli M, Mogimi N, McDullough LD, Rubinos CA, et al. Peripheral Nervous System Manifestations Associated with COVID-19. *Curr Neurol Neurosci Rep*. 2021;21(3):9.
107. Xu X, Wu X, Jiang X, Xu K, Ying L, Ma C et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series *BMJ* 2020; 368 :m606
108. Nersesjan V, Amiri M, Lebech AM, Roed C, Mens H, Russell L, et al. Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up [published online ahead of print, 2021 Jan 13]. *J Neurol*. 2021;1-19.



109. Goettler CE, Pryor JP, Reilly PM. Brachial plexopathy after prone positioning. *Critical care* (London, England). 2002;6(6):540–542.
110. Toscano G., Palmerini F., Ravaglia S., Ruiz L., Invernizzi P., Cuzzoni M.G., et al. Guillain-Barre Syndrome Associated with SARS-CoV-2. *N. Engl. J. Med.* 2020;382:2574–2576.
111. Rahimi K. Guillain-Barre syndrome during COVID-19 pandemic: An overview of the reports. *Neurol. Sci.* 2020;41:3149–3156.
112. Zhao H., Shen D., Zhou H., Liu J., Chen S. Guillain-Barre syndrome associated with SARS-CoV-2 infection: Causality or coincidence? *Lancet Neurol.* 2020;19:383–384.
113. Gupta A., Paliwal V.K., Garg R.K. Is COVID-19-related Guillain-Barre syndrome different? *Brain Behav. Immun.* 2020;87:177–178.
114. Ahmad I., Rathore F.A. Neurological manifestations and complications of COVID-19: A literature review. *J. Clin. Neurosci.* 2020;77:8–12.
115. Gutierrez-Ortiz C., Mendez-Guerrero A., Rodrigo-Rey S., San Pedro-Murillo E., Bermejo-Guerrero L., Gordo-Manas R., et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. *Neurology.* 2020;95:e601–e605.
116. Eshak N, Abdelnabi M, Ball S, Elgwairi E, Creed K, Test V, et al. Dysautonomia: An Overlooked Neurological Manifestation in a Critically ill COVID-19 Patient. *Am J Med Sci.* 2020;360(4):427-429.
117. Pourfridoni M, Pajokh M, Seyedi F. Bladder and bowel incontinence in COVID-19. *J Med Virol.* 2021 May;93(5):2609-2610.
118. Restivo DA, Centonze D, Alesina A, Marchese-Ragona R. Myasthenia gravis associated with SARS-CoV-2 infection. *Ann Intern Med.* 2020;173(12):1027–1028.
119. Camelo-Filho AE, Silva AMS, Estephan EP, Zambon AA, Mendonça RH, Souza PVS, et al. Myasthenia gravis and COVID-19: clinical characteristics and outcomes. *Front Neurol.* 2020;11:1053.
120. Ibarra-Coronado EG, Pantaleon-Martinez AM, Velazquez-Moctezuma J, Prospero-Garcia O, Mendez-Diaz M, Perez-Tapia M, et al. The Bidirectional Relationship between Sleep and Immunity against Infections. *J Immunol Res.* 2015;2015:678164.
121. Gupta R, Pandi-Perumal SR. COVID-Somnia: How the Pandemic Affects Sleep/Wake Regulation and How to Deal with it? [published online ahead of print, 2020 Dec 3]. *Sleep Vigil.* 2020;1-3.
122. Tony AA, Tony EA, Ali SB, Ezzeldin AM, Mahmoud AA. COVID-19-associated sleep disorders: a case report. *Neurobiol Sleep Circadian Rhythms.* 2020;9:100057.

123. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236–379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry*. 2021;8(5):416-427.
124. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397(10270):220-232.
125. Jiang Z, Zhu P, Wang L, Hu Y, Pang M, Ma S, et al. Psychological distress and sleep quality of COVID-19 patients in Wuhan, a lockdown city as the epicenter of COVID-19. *J Psychiatr Res*. 2021;136:595-602.
126. Miskowiak KW, Johnsen S, Sattler SM, Nielsen S, Kunalan K, Rungby J, et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. *Eur Neuropsychopharmacol*. 2021;46:39-48.
127. Wilcox ME, Brummel NE, Archer K, Ely EW, Jackson JC, Hopkins RO. Cognitive dysfunction in ICU patients: risk factors, predictors, and rehabilitation interventions. *Crit Care Med*. 2013;41(9 Suppl 1):S81-S98.
128. Hampshire A, Trender W, Chamberlain R, Jolly A, Grant J, Patrick F, et al. Cognitive deficits in people who have recovered from COVID-19 relative to controls: An N=84,285 online study. *medRxiv* 2020.10.20.20215863
129. Nauen DW, Hooper JE, Stewart CM, Solomon IH. Assessing Brain Capillaries in Coronavirus Disease 2019 [published online ahead of print, 2021 Feb 12]. *JAMA Neurol*. 2021;e210225.
130. Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. *Brain Behav Immun*. 2020;87:34-39.
131. Nakamura ZM, Nash RP, Laughon SL, Rosenstein DL. Neuropsychiatric Complications of COVID-19. *Curr Psychiatry Rep*. 2021;23(5):25.
132. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. *Brain Behav Immun*. 2020;89:594-600.
133. Cai X, Hu X, Ekumi IO, Wang J, An Y, Li Z, Yuan B. Psychological Distress and Its Correlates Among COVID-19 Survivors During Early Convalescence Across Age Groups. *Am J Geriatr Psychiatry*. 2020 Oct;28(10):1030-1039.
134. Parker C, Shalev D, Hsu I, Shenoy A, Cheung S, Nash S, et al. Depression, Anxiety, and Acute Stress Disorder Among Patients Hospitalized With COVID-19: A Prospective Cohort Study. *J Acad Consult Liaison Psychiatry*. 2021;62(2):211-219.

135. Ma YF, Li W, Deng HB, Wang L, Wang Y, Wang P, et al. Prevalence of depression and its association with quality of life in clinically stable patients with COVID-19. *J Affect Disord.* 2020;275:145-148.
136. Nie XD, Wang Q, Wang MN, Zhao S, Liu L, Zhu YL, et al. Anxiety and depression and its correlates in patients with coronavirus disease 2019 in Wuhan. *Int J Psychiatry Clin Pract.* 2021;25(2):109-114.
137. Nalleballe K, Reddy Onteddu S, Sharma R, Dandu V, Brown A, Jasti M, et al. Spectrum of neuropsychiatric manifestations in COVID-19. *Brain Behav Immun.* 2020;88:71-74.
138. Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci.* 2021;24(2):168-175.
139. Rhea EM, Logsdon AF, Hansen KM, Williams LM, Reed MJ, Baumann KK, et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. *Nat Neurosci.* 2021;24(3):368-378.
140. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarankul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. *J Thromb Haemost.* 2020;18(7):1738-1742.
141. Kreye J, Reincke SM, Prüss H. Do cross-reactive antibodies cause neuropathology in COVID-19? *Nat Rev Immunol.* 2020 Nov;20(11):645-646.
142. Jasti M, Nalleballe K, Dandu V, Onteddu S. A review of pathophysiology and neuropsychiatric manifestations of COVID-19. *J Neurol.* 2020 Jun 3:1–6.
143. Pérez CA. Looking ahead: The risk of neurologic complications due to COVID-19. *Neurol Clin Pract.* 2020 Aug;10(4):371-374
144. Bo HX, Li W, Yang Y, Wang Y, Zhang Q, Cheung T, et al. Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. *Psychol Med.* 2021;51(6):1052-1053
145. Chang MC, Park D. Incidence of Post-Traumatic Stress Disorder After Coronavirus Disease. *Healthcare (Basel).* 2020;8(4):373.
146. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *J Med Virol.* 2021;93(2):1013-1022.
147. Yang Y, Li W, Zhang Q, Zhang L, Cheung T, Xiang YT. Mental health services for older adults in China during the COVID-19 outbreak. *Lancet Psychiatry.* 2020;7(4):e19

148. Ahmed H, Patel K, Greenwood DC, Halpin S, Lewthwaite P, Salawu A, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. *J Rehabil Med.* 2020;52(5):jrm00063.
149. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Prevalence and Determinants of Fatigue after COVID-19 in Non-Hospitalized Subjects: A Population-Based Study. *Int J Environ Res Public Health.* 2021;18(4):2030.
150. Simani L, Ramezani M, Darazam IA, Sagharichi M, Aalipour MA, Ghorbani F, et al. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. *J Neurovirol.* 2021;27(1):154-159.
151. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. *PLoS One.* 2020;15(11):e0240784.
152. Islam M, Cotler J, Jason L. (2020). Post-viral fatigue and COVID-19: lessons from past epidemics. *Fatigue: Biomedicine, Health & Behavior.* 8. 1-9. 10.1080/21641846.2020.1778227.
153. Komaroff AL, Bateman L. Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?. *Front Med (Lausanne).* 2021;7:606824.
154. Woo MS, Malsy J, Pöttgen J, Seddiq Zai S, Ufer F, Hadjilou A, et al. Frequent neurocognitive deficits after recovery from mild COVID-19. *Brain Commun.* 2020;2(2):fcaa205.